NCT06188286

Brief Summary

The conduct of a pilot trial is of great significance as a means of assessing the feasibility and harmonization of the research and is a very necessary precursor to the better conduct of formal trials. The primary aim of this pilot study is to assess the feasibility of a PC-TEAS in improving the quality of life of cancer patients with pain, with the aspiration of providing process evidence base and an assessment of the intervention for conducting a formal trial. the secondary outcome is to assess the clinical efficacy of the PC-TEAS.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
94

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 18, 2023

Completed
16 days until next milestone

First Posted

Study publicly available on registry

January 3, 2024

Completed
12 months until next milestone

Study Start

First participant enrolled

December 25, 2024

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2025

Completed
Last Updated

December 24, 2024

Status Verified

December 1, 2024

Enrollment Period

10 months

First QC Date

December 18, 2023

Last Update Submit

December 19, 2024

Conditions

Keywords

transcutaneous electrical nerve stimulation

Outcome Measures

Primary Outcomes (1)

  • Trial feasibility

    The feasibility of the proposed approach will be evaluated by the number who agreed to participate in the trial.

    week 4

Secondary Outcomes (6)

  • the changes of EORTC QLQ-C30 score from baseline

    week 4, week 8, week 12

  • the changes in BPI score of mean pain, severe Pain, least pain and current pain from baesline

    week 4, week 8, week 12

  • the amounts of analgesics used

    week 4, week 8, week 12

  • Index of spontaneous bowel movements

    week 4, week 8, week 12

  • The changes in mood scale scores of Hamilton Rating Scale for Depression (HAM-D)

    week 4, week 8, week 12

  • +1 more secondary outcomes

Study Arms (2)

TEAS

ACTIVE COMPARATOR

transcutaneous acupoint electrical stimulation was performed at the bilateral Hegu and Waiguan acupoints for 30 minutes, and then transcutaneous acupoint electrical stimulation was performed at the Sanyinjiao and Zusanli acupoints of the bilateral lower limbs for 30 minutes.

Other: Transcutaneous electrical acupoint stimulation

sham TEAS

PLACEBO COMPARATOR

Except for the transcutaneous acupoint electrical stimulator, which has no current output, the other operations are the same as TEAS group

Other: sham Transcutaneous electrical acupoint stimulation

Interventions

The 4 patches of the transcutaneous acupoint electrical stimulator were pasted on two pairs of acupuncture points, the output frequency was adjusted to 2Hz, the intensity was up to 50ma, the single intervention time was 30 minutes, and another group of acupuncture points was replaced after completion, and the rest of the operations were the same as above, with a total intervention time of 1 hour.

TEAS

The patch is fixed on the acupuncture point to turn on the instrument, but there is no current output

sham TEAS

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Cancer Pain

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 18, 2023

First Posted

January 3, 2024

Study Start

December 25, 2024

Primary Completion

October 31, 2025

Study Completion

December 30, 2025

Last Updated

December 24, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share